在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。
Александра Лисица (Редактор отдела «Забота о себе»)，这一点在服务器推荐中也有详细论述
Essential digital access to quality FT journalism on any device. Pay a year upfront and save 20%.。51吃瓜对此有专业解读
Whatever the case, a wounded ISS will have been fairly rotten luck. Back in 2017, scientists from NASA and a Russian space contractor put the odds of this worst-case scenario at 1 in 121. As of late 2025, NASA told WIRED the risk of debris causing a depressurization event in any six-month period was somewhere between 1 in 36 and 1 in 170.，这一点在safew官方下载中也有详细论述